2023 group results (IFRS)
Feb 13 (Reuters)-
Sosei Group Corp
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Dec 31, 2023 Dec 31, 2022 Dec 31, 2024 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 12.77 15.57
(-18.0 pct) (-12.1 pct)
Operating loss 9.53 3.44
(-9.0 pct)
Pretax loss 10.68 1.08
(+149.0 pct)
Net loss 7.19 382 mln
(-62.4 pct)
EPS Basic loss 87.18 yen 4.68 yen
EPS Diluted loss 87.18 yen 4.63 yen
Ann Div NIL NIL NIL
-Q2 Div NIL NIL NIL
-Q4 Div NIL NIL NIL
NOTE - Sosei Group Corp.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up